29 C
Vientiane
Monday, November 3, 2025
spot_img
Home Blog Page 912

RESEARCH ADVANCES FROM THE 2025 ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE

TORONTO, July 31, 2025 /PRNewswire/ — New research results reported at the Alzheimer’s Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer’s disease and other dementias. Highlights include:

  • Two lifestyle interventions in the U.S. POINTER clinical trial improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention, helping to protect against normal age-related decline for up to two years.
  • The Alzheimer’s Association released its first clinical practice guidelines on use of blood biomarker tests by specialists to assist in the diagnosis of Alzheimer’s disease.
  • Taking a combination of common drugs to treat blood pressure, cholesterol and diabetes may slow cognitive decline, according to data from five studies.
  • Lead in the atmosphere and environment may be linked to memory problems 50 years later, based on a study of more than 600,000 people.
  • Walking and other lifestyle interventions could benefit people with the strongest known genetic risk for Alzheimer’s disease, the APOE4 gene variant.
  • The first results from “real world” studies of new amyloid targeting Alzheimer’s drugs confirmed findings from the late-stage clinical trials, and patients expressed satisfaction.
  • Participation in the U.S. Supplemental Nutrition Assistance Program (SNAP) is linked to slower cognitive decline, according to a first-of-its-kind long-term study.
  • New research gives insights into critical sex-based differences in brain health, including how traumatic brain injuries impact women and men differently, and new understanding of cognitive symptoms for women undergoing chemotherapy for breast cancer.

AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer’s and dementia research. This year’s conference in Toronto attracted nearly 19,000 registered attendees and included more than 6,400 scientific submissions.

Positive Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Study 
The Alzheimer’s Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) — a two-year, multi-site clinical trial testing two different lifestyle interventions in a representative population of older adults at risk for cognitive decline and dementia — found that both interventions improved cognition in older adults at risk of cognitive decline.

Trial participants in the structured intervention showed greater improvement on global cognition compared to the self-guided intervention, helping to protect against normal age-related decline for up to two years. This means that, relative to the self-guided group, participants in the structured group performed at a level comparable to adults one to nearly two years younger in age — an effect that likely increases resilience against cognitive decline.

This extra benefit was similar across all subgroups of U.S. POINTER participants — regardless of sex, ethnicity, genetic risk or heart health (blood pressure, cholesterol, and glucose levels). More than 30% of participants were from groups that have been historically underrepresented in dementia research.

Both interventions focused on increasing physical activity, improving nutrition, cognitive and social challenge, and health monitoring. The structured intervention differed from the self-guided intervention in intensity, structure, accountability and the support provided.

U.S. POINTER was a large-scale, rigorous, randomized controlled clinical trial. These positive results underscore the message that healthy behavior has a powerful impact on brain health, and encourage us to look at the potential for a combination of a lifestyle program and drug treatment as the next frontier in the fight against cognitive decline and possibly dementia.

Read the press release on U.S. POINTER study results.

First Clinical Practice Guideline For Blood Biomarker Tests in Alzheimer’s Diagnosis
The Alzheimer’s Association released its first evidence-based clinical practice guideline (CPG) on the use of blood-based biomarker (BBM) tests at AAIC 2025, a big step toward transforming Alzheimer’s diagnosis and management in specialty care settings. The CPG provides rigorous, evidence-based recommendations to help specialist clinicians to use BBM tests more confidently and consistently.

The recommendations are aimed at a variety of specialists in settings like neurology, psychiatry, geriatrics and more who diagnose and evaluate cognitive impairment, and are based on a review of available evidence through November 2024.

The recommendations suggest that specialists can use BBM tests as a triaging tool in the diagnostic workup of Alzheimer’s when they have at least 90% sensitivity and 75% specificity, but a positive triaging test should always be confirmed with more traditional tests like cerebral spinal fluid (CSF) or amyloid positron emission tomography (PET) imaging. The guidelines permit BBM tests with at least 90% sensitivity and 90% specificity to substitute for PET imaging or CSF testing. However, experts caution that many commercially available BBM tests do not yet meet these thresholds.

This CPG is part of ALZPro from the Alzheimer’s Association, the comprehensive hub of resources and tools for health care professionals and researchers from across disciplines to reduce risk, advance early detection, improve care and expand equitable access for all communities.

Read the press release on clinical practice guidelines for blood-based biomarker tests.

Combination of Heart-Health Drugs May Also Protect the Brain
Taking a combination of common drugs used to treat blood pressure, cholesterol and diabetes may have an added benefit: slower cognitive decline. A study of more than 4,500 older adults showed cognitive test scores similar to people three years younger for participants who took a combination of drugs targeting vascular or metabolic conditions, all of which are known risk factors for dementia.

Participants who were on all three of the vascular drugs had the greatest cognitive benefits, and their brains showed fewer signs of Alzheimer’s-related changes at autopsy. For those who took only two of the drugs, the most effective pairing for cognitive protection was blood pressure and cholesterol drugs.

Lead Pollution Linked to Memory Problems in Older Adults
Historic pollution levels from the era of leaded gasoline may be contributing to cognitive issues 50 years later, according to a first-of-its-kind research study. Researchers tracked how exposure to airborne lead from 1960-1974 — when leaded gasoline use was at its highest — impacted brain health later in life. The report estimated that half the U.S. population at that time, more than 170 million people, were exposed to high lead levels in early childhood.

The researchers linked the pollution data from the 60s and 70s to a contemporary study conducted between 2012 and 2017. They estimated that 17 to 22% of people living in areas with moderate or high atmospheric lead reported memory issues. While leaded gas has long been phased out, other sources of exposure remain, such as old lead paint, pipes and industrial pollution. Experts say people who had past lead exposure should focus on reducing other risk factors for dementia, including managing high blood pressure, quitting smoking and avoiding social isolation.

Read the press release on lead pollution and memory problems.

Lifestyle Change Benefits May Be Strongest for Carriers of Alzheimer’s Risk Gene
People with a higher genetic risk for Alzheimer’s disease may benefit the most from healthy lifestyle interventions like walking, according to a decade of data from three large international studies. Older adults who carry the Alzheimer’s risk gene known as APOE4 had higher cognitive benefits from non-drug interventions like exercise, diet and cognitive training than non-carriers.

In this study, walking was found to be the most effective healthy habit for slowing down cognitive damage. Like many healthy lifestyle changes, the key was making it a habit, as the study showed that sticking with it for at least two years produced cognitive benefits up to seven years later.

Participants in SNAP Food Assistance Program Had Slower Cognitive Decline
People who participated in the U.S. Supplemental Nutrition Assistance Program (SNAP) had slower cognitive decline over 10 years than non-participants, according to new research reported at AAIC 2025. Scientists examined data from the nationally representative Health and Retirement Study to compare participants in SNAP, which helps low-income individuals and families buy food, to those who were eligible for the program but didn’t participate.

They found that SNAP participants had a 0.10% slower decline in overall cognitive function. The difference is significant in the long-term, adding up to an estimated two to three additional years of cognitive health over the study’s 10-year period.

The study group of 1,131 SNAP participants studied included Whites, Blacks and Hispanics. A control group included 1,216 people who were SNAP-eligible but didn’t participate. Researchers found that all groups benefitted, but White participants showed much slower decline than other groups. The findings highlight the potential benefits of food assistance programs to support older adults’ cognitive health.

Read the press release on SNAP benefits and slower cognitive decline.

Real-World Results for New Alzheimer’s Drugs Show Effectiveness, Patient Satisfaction
While newly available anti-amyloid Alzheimer’s disease drugs have shown effectiveness in tightly controlled clinical trials, they have not been tested in real-world settings until now. Dozens of abstracts reported at AAIC 2025 showed that real world experience with the drugs lecanemab and donanemab produced comparable or better safety to large clinical trials, and patients were satisfied with the results.

Researchers tracked the drugs’ safety and effectiveness in patients from a variety of settings including U.S. clinics, memory care centers and international universities. Several of the sites are part of the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), which was created by the Alzheimer’s Association to collect voluntary real-world data about patients receiving the new treatments, track their long-term health, and share data with scientists and clinicians.

New Insights Into Cognitive Health Differences Between Men and Women
New research announced at AAIC 2025 sheds light on crucial differences between men and women in risk for Alzheimer’s and other diseases that cause dementia. One study found that traumatic brain injuries (TBIs, a well-known risk factor for dementia) were more likely to shrink dementia-related areas of the brain in women than men. Another looked closer at “chemobrain” — declines in thinking and memory reported by about one-third of women receiving breast cancer chemotherapy.

Women make up nearly two-thirds of the more than 7 million Americans living with Alzheimer’s. The chemobrain study is the first to show that brain changes, inflammation and shrinkage related to the cancer treatment are connected to symptoms like memory lapses and trouble focusing or finding words. The study adds to growing evidence that chemotherapy impacts brain health.

The Alzheimer’s Association supports research to better understand sex-based differences in cognitive health and prevent negative side effects for chemo patients. Clinicians can learn more about early detection, diagnosis and treatment of dementia using ALZPro, the newly-launched library of online tools and resources for professionals from the Alzheimer’s Association.

The Alzheimer’s Association extends a thank you to the AAIC 2025 Platinum Sponsors: Biogen, Eisai, Lilly and Novo Nordisk.

About the Alzheimer’s Association International Conference® (AAIC®)
The Alzheimer’s Association International Conference (AAIC) is the world’s largest gathering of researchers from around the world focused on Alzheimer’s and other dementias. As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
AAIC 2025 home page: www.alz.org/aaic/
AAIC 2025 newsroom: www.alz.org/aaic/pressroom.asp
AAIC 2025 hashtag: #AAIC25

About the Alzheimer’s Association®
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call 800.272.3900.

Zilliz Sets New Industry Standard with VDBBench 1.0 for Benchmarking Real Vector Database Production Workloads

This Open-source solution eliminates the multi-billion-dollar gap between benchmark promises and production reality.

REDWOOD CITY, Calif. , July 31, 2025 /PRNewswire/ — Zilliz, the company behind the popular open-source vector database Milvus, recently announced the release of VDBBench 1.0, an open-source benchmarking platform designed to test vector databases under realistic production conditions. Unlike traditional benchmarks that rely on static data and idealized scenarios, VDBBench evaluates systems during streaming data ingestion, metadata filtering, and concurrent workloads that mirror actual enterprise deployments.

“The vector database market has experienced explosive growth since 2023, but our benchmarking methodologies haven’t kept pace,” said James Luan, VP of Engineering at Zilliz. “Organizations are making multi-million dollar infrastructure decisions based on misleading benchmarks that don’t reflect production realities. VDBBench 1.0 fundamentally changes this dynamic by establishing new standards for authentic, production-relevant performance evaluation.”

What’s New in VDBBench 1.0
  • Advanced Filtering Analysis: Systematically tests metadata filtering across selectivity levels (50% to 99.9%), revealing the “hidden performance killer” that dramatically impacts query speeds and recall accuracy in production.
  • Streaming Read/Write Testing: Simulates continuous data ingestion while serving queries, conditions where many databases fail despite impressive static benchmarks.
  • Modern Datasets: Uses vectors from state-of-the-art embedding models, including OpenAI and Cohere, with dimensions ranging from 768 to 1,536, reflecting current AI workloads.
  • Custom Dataset Support: Organizations can benchmark using their production data and embedding models for industry-specific testing requirements.
  • Production-Focused Metrics: Prioritizes P95/P99 tail latency, sustainable throughput under load, and recall accuracy for realistic capacity planning.

VDBBench also features a redesigned dashboard with interactive visualizations that help engineers quickly identify performance gaps. Testing results for major platforms including Milvus, Zilliz Cloud, Pinecone, and Elasticsearch are available on the VDBBench Leaderboard.

Open Source Availability

VDBBench is available on GitHub with complete documentation and community support. Organizations ready to move beyond misleading benchmarks can access the platform immediately and customize it for specific testing requirements.

Download VDBBench 1.0 → | View Leaderboard → | Contact us for Support

About Zilliz

Zilliz builds next-generation database technologies that help organizations unlock the value of unstructured data and rapidly develop AI applications. Headquartered in Redwood Shores, California, Zilliz is backed by leading investors, including Aramco’s Prosperity7 Ventures and Temasek’s Pavilion Capital. Learn more at www.zilliz.com.

 

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer

SUZHOU, China, July 31, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study in the United States (study number: JSKN003-202) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, not restricted to HER2 expression levels.

JSKN003 is an anti-HER2 biparatopic ADC developed inhouse which can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated significant differentiated advantages including better serum stability and stronger bystander effect, which effectively expands the therapeutic window. In multiple clinical studies at various stages in China and Australia, JSKN003 has shown promising tolerability, safety, and significant antitumor activity.

In China, three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing breast cancer (BC), platinum-resistant ovarian cancer (PROC), and HER2-positive BC are currently undergoing smoothly. In March 2025, JSKN003 was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) for the treatment of PROC, not restricted to HER2 expression levels.

JSKN003-202 is a randomized, open-label, multi-center Phase II clinical study aimed at evaluating the safety and efficacy of JSKN003 in the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, and determine the recommended phase III dose (RP3D). The FDA approval of this U.S. Phase II trial marks a significant milestone in Alphamab Oncology’s global development strategy for its innovative pipeline, which will further strengthen the Company’s competitive edge in oncology therapeutics.

About JSKN003

JSKN003 is a bispecific ADC developed based on KN026 using Alphamab’s proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window.

Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. It has also been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ). Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly.

In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the “Field”) in mainland China (excluding Hong Kong, Macau or Taiwan) (the “Territory”) and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003.

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.

By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

 

FRV Announces Strategic Partnership with Envision, a Leader in Total Renewable Energy Solutions, for H2 Cumbuco Project in Brazil

MADRID, July 31, 2025 /PRNewswire/ — Fotowatio Renewable Ventures (FRV), part of Jameel Energy, announced today its selection of Envision Energy (“Envision’) as its strategic partner in green ammonia project in Brazil. Envision has been selected for its leadership and proven expertise across a total renewable energy system, from renewables through to green hydrogen – all orchestrated by AI technology.

FRV Announces Strategic Partnership with Envision for H2 Cumbuco Project in Brazil
FRV Announces Strategic Partnership with Envision for H2 Cumbuco Project in Brazil

This agreement will see Envision bringing to H2 Cumbuco – a landmark green ammonia project located in Brazil’s Pecém Port its globally recognized expertise in integrated renewable energy solution, building on its pioneering scalable clean energy models that are modular and replicable across the world.

The partnership brings together FRV’s extensive experience in clean energy solutions —backed by 3 GW of operational renewable and storage assets—and Envision’s AI-integrated total renewable energy system to build an electrolysis facility of up to 500MW electrolysis facility and an integrated ammonia plant, which is expected to be operational by 2030 and targeting key markets in Brazil, Europe and Asia.

This collaboration is more than a step towards decarbonization; it is a blueprint for how global energy transition can be operationalized. Together with FRV, we are reshaping the entire renewable energy system and advancing Brazil’s green energy infrastructure.” said Henry Peng, Senior Vice President and President of Latin America and the European Region.

Envision recently delivered the world’s largest off-grid AI-enabled green hydrogen and ammonia plant and its first green marine ammonia bunkering operation in Dalian, China – proof of its capability to orchestrate complex and total renewable solutions at scale.

FRV (Fotowatio Renewable Ventures) is a leading developer of sustainable energy solutions with a deep commitment to accelerating the energy transition. With a strong presence across key international markets—including Europe, Australia, Middle East, and Latin America—FRV continues to drive innovation and sustainability in the renewable energy sector.

Aligned with this commitment, FRV has also been actively engaged for several years in the development of renewable hydrogen projects. In Spain, the company has secured public funding for two green hydrogen-related initiatives.

In line with this strategy and leveraging on FRV’s long presence and commitment in Brazil, FRV has been developing the H2 Cumbuco project in Brazil since 2023. The project is in advanced development in areas such as engineering and environmental permitting, and has secured key resources, including land and water rights.

“At FRV, we firmly believe that the development of renewable hydrogen and its derivatives is a fundamental pillar in advancing global decarbonization. We see Brazil as a country with the potential to become a global leader in this sector, thanks to its strategic geographic position, strong commitment to the energy transition, and broad public support. We are excited about the potential that this alliance with Envision can bring to the H2 Cumbuco project, in order to provide clean, competitive, and sustainable energy solutions while supporting Brazil’s economic and environmental development,” stated Felipe Hernández, Chief Innovation Officer of FRV.

This partnership comes as Brazil, host of COP30 this year, develops a competitive low carbon economy with a focus on green hydrogen and green ammonia production not just for its domestic market, but for export to other parts of the world.

Confucius Academy Held a Yangming Cultural and Creative Show to Promote Chinese Culture

GUIYANG, China, July 31, 2025 /PRNewswire/ — A news report by Huanqiu.com

At 4 p.m. on June 2, the “Mind Quest Between Heaven and Earth: 2025 (Year of Yisi) Dragon Boat Festival Yangming Cultural and Creative Show at the Confucius Academy” successfully concluded, which attracted more than 20,000 visitors.

The event ingeniously combined the elements of cultural and creative products, traditional festival, and intangible cultural heritage techniques, realizing the cross-temporal brainstorming between Qu Yuan and Wang Yangming, the artistic presentation of the wisdom of the Mind Study and the patriotic sentiments towards the country and family, and the empowerment of a cultural and creative brand by thematic activities. The Confucius Academy’s new “cultural dissemination” pattern featuring “human, scenario and venue” is innovatively shaping a new cultural cluster and a new cultural IP for Guizhou Province.

Cultivating festival-themed IP

Concentrating on the triple functional orientations of education, research and dissemination, the Confucius Academy has actively integrated festival customs and cultural connotations into traditional Chinese festivals including the Spring Festival, Tomb-Sweeping Festival, Dragon Boat Festival and Mid-Autumn Festival, and successfully developed the IP of “Our Festivals”.

In this Dragon Boat Festival, the Confucius Academy focused on Guizhou’s “Four Cultural Programs” to deeply absorb the revolutionary culture, Yangming culture, ethnic culture and Tunpu (military outpost) culture.


During the Dragon Boat Festival holiday, Qu Yuan, transformed into a “cultural wanderer”, visited Wang Yangming to discuss on “Quest for Heavenly Truth” and “Study of the Mind” in a three-act cultural play. The “Riverside Odes” session combined an ethnic cultural fashion show and modern dance. Amidst the intermingling dancers, the models dressed in ethnic minority costumes showed the Yangming-themed cultural and creative products on the runway. The “Wang Yangming’s Quest for Truth” session presented a dance-poetry drama that a duet of Wang Yangming and Qu Yuan depicted their conversation on pursuing the truth between heaven and earth. The “Guizhou as Home” session was a fusion of Anshun Di Opera and modern dance, which followed Wang Yangming’s Study of the Mind as the soul, and “Tunpu’s sentiments towards the country and family” as the main thread to construct a spiritual dialogue spanning 600 years.

Combining strengths of incubation platforms

The Yangming Cultural and Creative Show is more than a cultural performance, but carries the mission of “bringing tradition into life”. At the event, the Confucius Academy in Guiyang invited a number of designers and intangible cultural heritage inheritors, and held a plaque-awarding ceremony for the “Confucius Academy’s Second-batch Partners of Yangming Cultural and Creative Incubation Platforms”.”

How can we creatively realize the revival of traditional Chinese culture and reproduce the natural charm and interest in history? Zhou Hang, creative director and designer of Animation Zhou Studio envisaged, “I hope to make use of we-media, funny animations and design capability to present the Yangming culture in a more accessible way to the world.”

Inspired by Wang Yangming’s Study of the Mind and the picturesque scenery of Guizhou, the “Yangming Cultural and Creative”, the inaugural cultural and creative brand of the Confucius Academy, had its debut at the event that more than 300 cultural and creative products were displayed, including bibelots, stationery, tea and water sets, and fragrance.

Providing intangible cultural heritage experience

In addition to cultural exhibition, the event also featured a “study tour”. Visitors showed great interest in the intangible cultural heritage workshops of lacquer fans, tie dyeing, paper cutting, woodcarving, tea cultivation, rope weaving, pottery art and Miao silverwork.

The sachet-making zone offered diverse Chinese medicinal herbs such as lemongrass, honeysuckle, albizia flower, mugwort leaf, mint and angelica. Visitors selected and mixed herbs for different effects, crushed them and then wrapped them in beautiful sachets to get special handmade souvenirs for the Dragon Boat Festival.

imToken, One of the Earliest Ethereum Mobile Wallets, Celebrates 10 Years of Ethereum in Singapore

SINGAPORE, July 31, 2025 /PRNewswire/ — On July 30, 2025, Ethereum celebrates its 10th anniversary since the genesis block was mined on July 30, 2015, marking a decade of global innovation in programmable blockchain, and a continuous record of zero downtime. To commemorate this milestone, imToken co‑hosted a celebration at the iconic ArtScience Museum alongside  Ethereum Singapore, featuring a keynote by Aya Miyaguchi, President of the Ethereum Foundation, and bringing together local developers, Ethereum OGs, and community leaders.

imToken co‑hosted Ethereum 10th celebration at the Singapore ArtScience Museum
imToken co‑hosted Ethereum 10th celebration at the Singapore ArtScience Museum

Over the past decade, Ethereum has achieved the extraordinary: powering a tokenized economy worth hundreds of billions with uninterrupted stability, reducing energy consumption by 99% post-Merge, and successfully balancing the blockchain trilemma without compromise.

As Ethereum turns 10, imToken reflects on the global movement ignited by the Ethereum Whitepaper—a vision that has inspired the company’s journey since 2016. imToken believes everything can be tokenized and that everyone should have equal access. This shared vision, aligned with Ethereum’s long-term goals and commitment to decentralization and responsible innovation, has helped both imToken and Ethereum stay the course through many challenges over the years.

Balancing the blockchain trilemma presents new challenges, and imToken is committed to addressing them. This year, imToken focuses on delivering a unified Ethereum experience through its “Token-centric” design and the newly launched imToken Web—a user-friendly blockchain interface that reduces friction for users to create accounts, participate in staking, access low-cost Layer 2 transactions, engage with decentralized applications across EVM-compatible chains, and capture the value of diverse tokens—including NFTs, cryptocurrencies, stablecoins, and real-world assets (RWA).

Just as Ethereum has maintained stability for a decade, imToken has also upheld its promise for nearly ten years—anchored in the vibrant heart of Singapore, the Lion City, and reaching toward a global future. Built on the core principle of being non-custodial and supported by a robust security architecture, imToken boasts an outstanding record of zero platform-native security incidents. As it enters a new decade, imToken is dedicated to working alongside builders across the Ethereum ecosystem to create an on-chain future that is secure, inclusive, and accessible to everyone worldwide.

KuCoin Celebrates African Women’s Day – Empowering Communities Through Crypto for Good

PROVIDENCIALES, Turks and Caicos Islands, July 31, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency exchange, today commemorates African Women’s Day by spotlighting its impactful corporate social responsibility (CSR) initiatives focused on gender equality, education, and sustainable development across Africa. This annual observance on July 31 honors the contributions of African women and aligns perfectly with KuCoin’s mission to leverage blockchain for global good.


In the past year, KuCoin’s CSR efforts have benefited over 50,000 individuals worldwide, earning the exchange the UNWWO 2025 Corporate Social Responsibility Award in March 2025 for advancements in Web3 financial inclusion, women’s health, children’s education, and climate resilience.

KuCoin is proud to stand with African women on this significant day, recognizing their vital role in community building and innovation,” said BC Wong, CEO of KuCoin. “Our CSR projects are designed to address real-world challenges, from energy access in rural Africa to menstrual equity globally, empowering women and girls to thrive in the digital economy.

Key Highlights of KuCoin’s CSR Efforts in Africa and Gender Equality:

  • Light Up Africa Initiative: Distributed 9,700+ solar lamps to children in Ghana, Nigeria, and Sierra Leone, enabling education for 50,000 young learners and supporting girls’ access to schooling amid energy poverty. Partnerships with local organizations ensure long-term impact.
  • Menstrual Equity Project: In collaboration with AMWA, provided 5,000 sustainable menstrual kits to over 5,000 women and girls globally, including expansions to 4,000 in the Bahamas, addressing health barriers and aligning with SDGs on gender equality. 
  • Women in Crypto Empowerment: Hosted events for International Women’s Day 2025, including giveaways and discussions on female leadership in Web3, with surveys showing women’s strong preference for long-term investments.

These projects demonstrate our long-term commitment to addressing real-world challenges powered by Web3 synergy, which includes donations for humanitarian causes and crypto adoption reports to promote financial inclusion in Africa.

KuCoin remains dedicated to expanding these efforts, inviting partnerships to further empower African communities. This year, KuCoin will further expand the “Light Up Africa” initiative, strengthening our support for education and sustainability in African communities, with ongoing preparations underway to enhance its reach. For more information, please visit KuCoin ESG Official Twitter.

About KuCoin

Founded in 2017, KuCoin is one of the pioneering and most globally recognized technology platforms supporting digital economies, built on a robust foundation of cutting-edge blockchain infrastructure, liquidity solutions, and an exceptional user experience. With a connected user base exceeding 41 million worldwide, KuCoin offers comprehensive digital asset solutions across wallets, trading, wealth management, payments, research, ventures, and AI-powered bots.

KuCoin has garnered accolades such as “Best Crypto Apps & Exchanges” by Forbes and has been recognized among the “Top 50 Global Unicorns” by Hurun in 2024. These recognitions reflect its commitment to user-centric principles and core values, which include integrity, accountability, collaboration, and a relentless pursuit of excellence. Learn more: https://www.kucoin.com/

Chipscreen Biosciences’ Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

SHENZHEN, China, July 31, 2025 /PRNewswire/ — Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”) announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its innovative drug CS231295 tablet for the treatment of advanced solid tumors. This significant milestone marks a key step forward in the global development strategy for CS231295.

Malignant tumors remain one of the leading causes of death worldwide. Despite continuous advancements in clinical treatments and efficacy, most cancers remain incurable. Drug resistance, recurrence, and metastasis pose significant threats to long-term patient survival. In particular, due to the presence of the blood-brain barrier, primary brain tumors and brain metastases not only pose a severe danger to life but also serve as natural barriers to effective drug therapy. Thus, developing novel brain-penetrant anti-cancer drugs has become a pressing challenge and a key research focus.

CS231295 is a next-generation brain-penetrant Aurora B selective inhibitor discovered through years of mechanism-based research by Chipscreen Biosciences. On one hand, it precisely inhibits tumor-specifically overexpressed Aurora B kinase to induce synthetic lethality, directly targeting the genetic vulnerability of hard-to-treat cancers such as those with RB1 deletion. On the other hand, due to its strong blood-brain barrier permeability, it shows significant therapeutic potential for both primary and metastatic brain tumors. Furthermore, this molecule also exhibits broad-spectrum anti-tumor activity, which improves the tumor microenvironment. It is expected to provide a novel solution for tumors with similar genetic defects and the global challenge of brain metastases. Currently, there is no similar compound with this design that has entered clinical trials globally.

With its unique mechanism and chemical structure, CS231295 demonstrates synergistic effects when combined with chemotherapy, targeted therapy, and cancer immunotherapy. In preclinical studies, CS231295 has shown remarkable pharmacodynamic activity, ideal pharmacokinetic properties, and a favorable safety profile.

Notably, CS231295 completed the first patient enrollment in its Phase I first-in-human clinical trial in China in May 2025, providing preliminary evidence to support the scientific rationale and feasibility of global multicenter clinical development. The FDA’s IND approval will further accelerate the initiation and implementation of its clinical research in the United States.

About Chipscreen Biosciences

Chipscreen Biosciences is an innovation-driven pharmaceutical company dedicated to developing globally competitive pipelines of first- and best-in-class original drugs. As a pioneer in China’s original drug innovation space, the company upholds the mission of “Innovation, Safety, Efficacy, China-Origin”. It is committed to delivering urgently needed, revolutionary mechanism-based therapies to patients. Chipscreen has established a comprehensive industrial chain, spanning from early discovery to commercialization, and offers innovative drug solutions originating from China to global patients.

Anchored by a global development strategy based on early-stage research in China, Chipscreen leverages its small-molecule R&D centers in Shenzhen and Chengdu, where experienced scientific teams have built an integrated technology platform powered by AI-assisted design and chemical genomics. This enables a seamless translation from fundamental research to clinical development. The company has successfully developed multiple first-in-class and best-in-class novel drugs. Two of its drugs covering six indications have been launched globally. The company maintains a diversified innovation pipeline across five major areas: oncology, metabolic diseases, autoimmune disorders, central nervous system diseases, and antivirals. As one of the first national “Innovative Drug Incubation Bases” and a certified National High-Tech Enterprise, Chipscreen has independently undertaken numerous national-level projects, including the “Major New Drug Innovation” initiative, and has filed over 700 patent applications globally, with more than 200 granted.

About Chipscreen Biosciences (USA) Ltd.

Founded in April 2021 and headquartered in New Jersey, Chipscreen Biosciences (USA) Ltd. is a wholly owned subsidiary of Chipscreen Biosciences. It is committed to advancing the clinical development of the company’s innovative drugs globally. Upholding the motto “Constant Innovation for Life,” the U.S. subsidiary has built a U.S.-based R&D platform to accelerate the clinical translation and global registration of drug candidates, including CS231295. Leveraging its parent company’s strong AI-assisted design and chemical genomics platforms, the U.S. team works closely with early R&D forces in China and international multicenter clinical networks, forming a globalized drug development system. The company will continue to drive the global advancement of CS231295 and aims to bring breakthrough therapies to patients with brain tumors and other unmet medical needs.